Literature DB >> 15994801

The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner.

Cheryl J Saunders1, Ruth A McCaffrey, Irina Zharkikh, Zane Kraft, Susan E Malenbaum, Brian Burke, Cecilia Cheng-Mayer, Leonidas Stamatatos.   

Abstract

It is well documented that removal of the V1V2 region or of the V2 loop alone from the envelope glycoprotein of human immunodeficiency virus type 1 (HIV-1) or simian immunodeficiency virus (SIV) increases the susceptibility of these viruses to neutralization by antibodies. The specific role of the V1 loop in defining the neutralization susceptibility of HIV is, however, not well documented. Our current studies indicate that although the V1V2 region is a global modulator of the HIV-1 neutralization susceptibility, the individual roles the V1 and V2 loops have in defining the neutralization susceptibility profile of HIV-1 differ and in some cases are opposite. While deletion of the V2 loop renders the virus more susceptible to neutralization by antibodies that recognize diverse epitopes, in particular certain ones located in the CD4 binding site and the V3 loop, deletion of the V1 loop renders the virus refractory to neutralization, especially by antibodies that recognize CD4-induced epitopes and certain CD4-site binding antibodies. Our current studies also indicate that the relative involvement of the V2 loop of the HIV-1 envelope during virus-cell entry appears to be envelope background dependent. As a result, although deletion of the V2 loop from the clade B, R5-tropic SF162 HIV-1 virus resulted in a virus that was replication competent, the same modification introduced on the background of two other R5-tropic isolates, SF128A (clade B) or SF170 (clade A), abrogated the ability of these envelopes to mediate virus-cell entry.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15994801      PMCID: PMC1168758          DOI: 10.1128/JVI.79.14.9069-9080.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120.

Authors:  C Rizzuto; J Sodroski
Journal:  AIDS Res Hum Retroviruses       Date:  2000-05-20       Impact factor: 2.205

2.  Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus.

Authors:  P D Kwong; R Wyatt; Q J Sattentau; J Sodroski; W A Hendrickson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  Naturally occurring V1-env region variants mediate simian immunodeficiency virus SIVmac escape from high-titer neutralizing antibodies induced by a protective subunit vaccine.

Authors:  H Petry; K Pekrun; G Hunsmann; E Jurkiewicz; W Lüke
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons.

Authors:  N L Haigwood; P L Nara; E Brooks; G A Van Nest; G Ott; K W Higgins; N Dunlop; C J Scandella; J W Eichberg; K S Steimer
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

5.  Relation of phenotype evolution of HIV-1 to envelope V2 configuration.

Authors:  M Groenink; R A Fouchier; S Broersen; C H Baker; M Koot; A B van't Wout; H G Huisman; F Miedema; M Tersmette; H Schuitemaker
Journal:  Science       Date:  1993-06-04       Impact factor: 47.728

6.  A single amino acid substitution in the V1 loop of human immunodeficiency virus type 1 gp120 alters cellular tropism.

Authors:  M T Boyd; G R Simpson; A J Cann; M A Johnson; R A Weiss
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

7.  V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.

Authors:  A Ly; L Stamatatos
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

8.  The N-terminal V3 loop glycan modulates the interaction of clade A and B human immunodeficiency virus type 1 envelopes with CD4 and chemokine receptors.

Authors:  S E Malenbaum; D Yang; L Cavacini; M Posner; J Robinson; C Cheng-Mayer
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

9.  Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions.

Authors:  R Wyatt; N Sullivan; M Thali; H Repke; D Ho; J Robinson; M Posner; J Sodroski
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

10.  Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.

Authors:  J P Moore; D D Ho
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

View more
  73 in total

1.  Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate.

Authors:  Junji Shibata; Kazuhisa Yoshimura; Akiko Honda; Atsushi Koito; Toshio Murakami; Shuzo Matsushita
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

2.  Unique mutational patterns in the envelope alpha 2 amphipathic helix and acquisition of length in gp120 hypervariable domains are associated with resistance to autologous neutralization of subtype C human immunodeficiency virus type 1.

Authors:  Rong Rong; S Gnanakaran; Julie M Decker; Frederic Bibollet-Ruche; Jesse Taylor; Jeffrey N Sfakianos; John L Mokili; Mark Muldoon; Joseph Mulenga; Susan Allen; Beatrice H Hahn; George M Shaw; Jerry L Blackwell; Bette T Korber; Eric Hunter; Cynthia A Derdeyn
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

3.  Isolation and characterization of monoclonal antibodies elicited by trimeric HIV-1 Env gp140 protein immunogens.

Authors:  Nina R Derby; Sean Gray; Elizabeth Wayner; Dwayne Campogan; Giorgos Vlahogiannis; Zane Kraft; Susan W Barnett; Indresh K Srivastava; Leonidas Stamatatos
Journal:  Virology       Date:  2007-06-08       Impact factor: 3.616

4.  Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses.

Authors:  Zane Kraft; Katharine Strouss; William F Sutton; Brad Cleveland; For Yue Tso; Patricia Polacino; Julie Overbaugh; Shiu-Lok Hu; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-04-09       Impact factor: 5.103

5.  Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches.

Authors:  Pawel Ciborowski
Journal:  Biomark Med       Date:  2009-12       Impact factor: 2.851

6.  HIV-1 Nef responsiveness is determined by Env variable regions involved in trimer association and correlates with neutralization sensitivity.

Authors:  Yoshiko Usami; Heinrich Göttlinger
Journal:  Cell Rep       Date:  2013-10-24       Impact factor: 9.423

7.  Role of V1V2 and other human immunodeficiency virus type 1 envelope domains in resistance to autologous neutralization during clade C infection.

Authors:  Rong Rong; Frederic Bibollet-Ruche; Joseph Mulenga; Susan Allen; Jerry L Blackwell; Cynthia A Derdeyn
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

8.  Molecular architecture of native HIV-1 gp120 trimers.

Authors:  Jun Liu; Alberto Bartesaghi; Mario J Borgnia; Guillermo Sapiro; Sriram Subramaniam
Journal:  Nature       Date:  2008-07-30       Impact factor: 49.962

9.  A comparative study of HIV-1 clade C env evolution in a Zambian infant with an infected rhesus macaque during disease progression.

Authors:  For Yue Tso; Federico G Hoffmann; Damien C Tully; Philippe Lemey; Robert A Rasmussen; Hong Zhang; Ruth M Ruprecht; Charles Wood
Journal:  AIDS       Date:  2009-09-10       Impact factor: 4.177

10.  Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection.

Authors:  D Noah Sather; Jakob Armann; Lance K Ching; Angeliki Mavrantoni; George Sellhorn; Zachary Caldwell; Xuesong Yu; Blake Wood; Steve Self; Spyros Kalams; Leonidas Stamatatos
Journal:  J Virol       Date:  2008-11-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.